Transthyretin-related hereditary amyloidosis

Revision as of 15:41, 4 January 2016 by Kiran Singh (talk | contribs) (Created page with "__NOTOC__ {{SI}} {{CMG}} ==Overview== '''Familial amyloid polyneuropathy''' (FAP), also called '''transthyretin-related hereditary amyloidosis''', '''transthyretin amyl...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for Transthyretin-related hereditary amyloidosis

Articles

Most recent articles on Transthyretin-related hereditary amyloidosis

Most cited articles on Transthyretin-related hereditary amyloidosis

Review articles on Transthyretin-related hereditary amyloidosis

Articles on Transthyretin-related hereditary amyloidosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Transthyretin-related hereditary amyloidosis

Images of Transthyretin-related hereditary amyloidosis

Photos of Transthyretin-related hereditary amyloidosis

Podcasts & MP3s on Transthyretin-related hereditary amyloidosis

Videos on Transthyretin-related hereditary amyloidosis

Evidence Based Medicine

Cochrane Collaboration on Transthyretin-related hereditary amyloidosis

Bandolier on Transthyretin-related hereditary amyloidosis

TRIP on Transthyretin-related hereditary amyloidosis

Clinical Trials

Ongoing Trials on Transthyretin-related hereditary amyloidosis at Clinical Trials.gov

Trial results on Transthyretin-related hereditary amyloidosis

Clinical Trials on Transthyretin-related hereditary amyloidosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Transthyretin-related hereditary amyloidosis

NICE Guidance on Transthyretin-related hereditary amyloidosis

NHS PRODIGY Guidance

FDA on Transthyretin-related hereditary amyloidosis

CDC on Transthyretin-related hereditary amyloidosis

Books

Books on Transthyretin-related hereditary amyloidosis

News

Transthyretin-related hereditary amyloidosis in the news

Be alerted to news on Transthyretin-related hereditary amyloidosis

News trends on Transthyretin-related hereditary amyloidosis

Commentary

Blogs on Transthyretin-related hereditary amyloidosis

Definitions

Definitions of Transthyretin-related hereditary amyloidosis

Patient Resources / Community

Patient resources on Transthyretin-related hereditary amyloidosis

Discussion groups on Transthyretin-related hereditary amyloidosis

Patient Handouts on Transthyretin-related hereditary amyloidosis

Directions to Hospitals Treating Transthyretin-related hereditary amyloidosis

Risk calculators and risk factors for Transthyretin-related hereditary amyloidosis

Healthcare Provider Resources

Symptoms of Transthyretin-related hereditary amyloidosis

Causes & Risk Factors for Transthyretin-related hereditary amyloidosis

Diagnostic studies for Transthyretin-related hereditary amyloidosis

Treatment of Transthyretin-related hereditary amyloidosis

Continuing Medical Education (CME)

CME Programs on Transthyretin-related hereditary amyloidosis

International

Transthyretin-related hereditary amyloidosis en Espanol

Transthyretin-related hereditary amyloidosis en Francais

Business

Transthyretin-related hereditary amyloidosis in the Marketplace

Patents on Transthyretin-related hereditary amyloidosis

Experimental / Informatics

List of terms related to Transthyretin-related hereditary amyloidosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Familial amyloid polyneuropathy (FAP), also called transthyretin-related hereditary amyloidosis, transthyretin amyloidosis abbreviated also as ATTR ( hereditary form), or Corino de Andrade's disease,[1] is an autosomal dominant[2] neurodegenerative disease. It is a form of amyloidosis, and was first identified and described by Portuguese neurologist Mário Corino da Costa Andrade, in 1952.[3] FAP is distinct from senile systemic amyloidosis (SSA), which is not inherited, and which was determined to be the primary cause of death for 70% of supercentenarians who have been autopsied.[4]

FAP can be ameliorated by liver transplantation.

Characteristics

Usually manifesting itself between 20 and 40 years of age, it is characterized by pain, paresthesia, muscular weakness and autonomic dysfunction. In its terminal state, the kidneys and the heart are affected. FAP is characterized by the systemic deposition of amyloidogenic variants of the transthyretin protein, especially in the peripheral nervous system, causing a progressive sensory and motor polyneuropathy.

Cause and genetics

File:Autosomal dominant - en.svg
Familial amyloid polyneuropathy has an autosomal dominant pattern of inheritance.

FAP is caused by a mutation of the TTR gene, located on human chromosome 18q12.1-11.2.[5] A replacement of valine by methionine at position 30 (TTR V30M) is the mutation most commonly found in FAP.[1] The variant TTR is mostly produced by the liver.[citation needed] The transthyretin protein is a tetramer. The tetramer has to dissociate into misfolded monomers to aggregate into a variety of structures including amyloid fibrils. Because most patients are heterozygotes, they deposit both mutant and wild type TTR subnits.

FAP is inherited in an autosomal dominant manner.[2] This means that the defective gene responsible for the disorder is located on an autosome (chromosome 18 is an autosome), and only one copy of the defective gene is sufficient to cause the disorder, when inherited from a parent who has the disorder.

Prognosis

In the absence of a liver transplant, FAP is invariably fatal, usually within a decade. The disadvantage of liver transplantation is that approximately 10% of the subjects die from the procedure or complications resulting from the procedure, which is a form of gene therapy wherein the liver expressing wild type and mutant TTR is replaced by a liver only expressing wild type TTR. Moreover, transplanted patients must take immune suppressants (drugs) for the remainder of their life, which can lead to additional complications. In late 2011, the European Medicines Agency approved the transthyretin kinetic stabilizer Tafamidis or Vyndaqel discovered by Jeffery W. Kelly and developed by FoldRx pharmaceuticals (acquired by Pfizer in 2010) for the treatment of FAP based on clinical trial data. Tafamidis (20 mg once daily) slowed the progression of FAP over a 36-month period and importantly reversed the weight loss and muscle wasting associated with disease progression.

Epidemiology

This disease is endemic in Portuguese locations Póvoa de Varzim and Vila do Conde (Caxinas), with more than 1000 affected people, coming from about 500 families, where 70% of the people develop the illness. In northern Sweden, more specifically Piteå, Skellefteå and Umeå, 1.5% of the population has the mutated gene. There are many other populations in the world who exhibit the illness after having developed it independently.

Regulatory Agency Approved Treatments

The drug tafamidis[6] has completed a phase II/III 18-month-long placebo controlled clinical trial[7] and these results in combination with an 18 month follow-on study demonstrated that Tafamidis or Vyndaqel slowed progression of FAP, particularly when administered to patients early in the course of FAP.[8] This drug is now approved by the European Medicines Agency.

The US Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee rejected the drug in June 2012, in a 13-4 vote.[9] The committee stated that there was not enough evidence supporting efficacy of the drug, and requested additional clinical trials.[10]

References

  1. 1.0 1.1 Online Mendelian Inheritance in Man (OMIM) 105210
  2. 2.0 2.1 Ando, Y.; Ueda, M. (May 2008). "Novel methods for detecting amyloidogenic proteins in transthyretin related amyloidosis". Frontiers in bioscience : a journal and virtual library. 13: 5548–5558. PMID 18508604.
  3. Andrade C (September 1952). "A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves". Brain. 75 (3): 408–27. doi:10.1093/brain/75.3.408. PMID 12978172.
  4. Coles LS, Young RD (2012). "Supercentenarians and transthyretin amyloidosis: the next frontier of human life extension". PREVENTATIVE MEDICINE. 54 (Suppl): s9–s11. doi:10.1016/j.ypmed.2012.03.003. PMID 22579241.
  5. Online Mendelian Inheritance in Man (OMIM) 176300
  6. Tafamidis structure
  7. Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis – ClinicalTrials.gov ref: NCT00409175
  8. http://protomag.ticsnetwork.com/statics/MGH_SP10_Protein_fold_F2.pdf
  9. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM304830.pdf
  10. http://www.bioworld.com/content/fda-delivers-crl-pfizers-rare-disease-drug-vyndaqel-0

External links


Amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Primary amyloidosis
Secondary amyloidosis
Familial amyloidosis
Wild-type (senile) amyloidosis
Cardiac amyloidosis
Beta-2 microglobulin related amyloidosis
Gelsolin related amyloidosis
Lysozyme amyloid related amyloidosis
Leucocyte cell-derived chemotaxin 2 related amyloidosis
Fibrinogen A alpha-chain associated amyloidosis

Pathophysiology

Causes

Differentiating Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Transthyretin-related hereditary amyloidosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Transthyretin-related hereditary amyloidosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Transthyretin-related hereditary amyloidosis

CDC on Transthyretin-related hereditary amyloidosis

Transthyretin-related hereditary amyloidosis in the news

Blogs on Transthyretin-related hereditary amyloidosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Transthyretin-related hereditary amyloidosis